IRE ELiT and Grand Pharmaceutical (China) Co., Ltd. announce partnership for Galli Eo (Gallium-68 generator) distribution in China

Fleurus (Belgium) and Wuhan (China), 06 June 2024, – IRE ELiT, a leading global player in the field of radiopharmaceuticals, is pleased to announce the signing of a distribution agreement with Grand Pharmaceutical (China) Co., Ltd. (“Grand Pharma”, and its subsidiary Chengdu Purevalley Medical Technology Co., Ltd.), a major pharmaceutical conglomerate, for the distribution of its Galli Eo (Gallium-68 generator) in China. This strategic partnership underscores IRE ELiT’s commitment to expanding its footprint in one of the most dynamic and rapidly growing markets for radiopharmaceuticals.

China, with its significant advancements in healthcare and an increasing demand for cutting-edge medical technologies, represents a pivotal market for IRE ELiT. The Galli Eo generator, known for its performance and reliability, will be instrumental in enhancing diagnostic capabilities and improving patient outcomes across the country.

“The professionalism and radiopharmaceutical expertise of the Grand Pharma team combined with the perfect integration of our respective products in the service of Chinese patients makes this partnership particularly relevant. We are very happy and proud to have Grand Pharma as our distributor of our Gallium-68 generator in China,” said Jean Bonnet, Head of Strategy at IRE ELiT. “China's healthcare sector is evolving at an unprecedented pace, and our partnership with Grand Pharma will enable us to bring our innovative solutions to a broader audience. Together, we are committed to advancing the field of nuclear medicine and delivering high-quality care to patients.”

Grand Pharma (and its subsidiary Chengdu Purevalley Medical Technology Co., Ltd.) brings extensive expertise and a robust distribution network, ensuring that the Galli Eo generator will reach medical hospitals and facilities across China efficiently. This collaboration marks a significant milestone for both companies, leveraging their strengths to meet the growing demand for advanced Ga-68 radiopharmaceuticals in the region.

For more information about IRE ELiT and the Galli Eo generator, please visit https://www.ire.eu/en/our-activities/ire-elit/galli-eo

About IRE ELiT

IRE ELiT, the innovation subsidiary of IRE, is a radiopharmaceutical company founded in 2010 to fully develop radiopharmaceuticals used in molecular imaging and therapy. IRE ELiT works closely with its clients in a «test & learn» spirit as well as with globally recognized universities and research centers. Today, IRE ELiT is one of only two global suppliers of germanium-68 (Ge-68)/gallium-68 (Ga-68) generators approved for use as a drug in Europe and as an active pharmaceutical ingredient (API) in the U.S. IRE and IRE ELiT currently employ 250 people. More information is available at www.ire.com

About Grand Pharma

Grand Pharma is an international pharmaceutical company of technological innovation. Its core businesses cover three major areas, namely pharmaceutical technology, nuclear medicine anti-tumour diagnosis and treatment and cerebro-cardiovascular precision interventional diagnosis and treatment technology and biotechnology. Based on the pharmaceutical and biological industries, Grand Pharma focuses on the needs of patients, and takes technological innovation as the driving force. In response to the unmet clinical needs, Grand Pharma will increase its investment in global innovative products and advanced technologies, enrich and improve its product pipelines, consolidate and strengthen its industrial chain layout, and fully leverage Grand Pharma’s industrial strengths and R&D capabilities to provide more advanced and diverse treatment solutions to patients worldwide. www.grandpharm.com/en/